explore -WSS

explore

author：comprehensive 2025-09-27 22:49:26 - browse：7822

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Astellas still sees hope in its gene therapy after four deaths

Wikipedia

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Unique patient identifier: Experts argue the benefits, pitfalls

A protest over insulin prices is seen as a fight for life

Adopting new red light myopia treatments may be short

Surge of respiratory disease in China has likely explanation

Medicare Advantage plans can’t deny care with AI, CMS warns

focus

explore

hotspot

Medical records are filled with copy

Texas Medical Board asked to define abortion emergency exception

United colonoscopy coverage change 'may cost lives,' doctors say

A single Democrat is willing to weaken Medicare negotiation power

How to save PrEP access — and even expand it

Cano Health’s bankruptcy is a warning for Medicare Advantage

Dobbs anniversary: the lost opportunity of abortion as health care

What’s missing from the debate over nursing home staff minimums

How one medical school became remarkably diverse

Padmanee Sharma of MD Anderson at center of lawsuit over credit

explore

Poor hospice wound care hurts patients and families

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Unique patient identifier: Experts argue the benefits, pitfalls

Cano Health’s bankruptcy is a warning for Medicare Advantage

Weight loss drug costs may need more research, senator suggests

Weight loss drug costs may need more research, senator suggests

focus

Wikipedia

leisure time

knowledge